HomeCONGRESS

CONGRESS

View Category
Acute coronary syndromes

ESC 2019 | ISAR-REACT 5 | Which Is Better in ACS, Prasugrel or Ticagrelor?

Courtesy of Dr. Carlos Fava. The benefit of dual antiplatelet therapy in acute coronary syndromes (ACS) has been...
solaci -
Learn More
ESC 2019

ESC 2019

Here you will find the highlights of the ESC 2019 Congres, held on August 31st to September...
solaci -
Learn More
Other

ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.

The combination Sacubitril/valsartan did not reduce the risk of rehospitalization for heart failure or cardiovascular death in...
solaci -
Learn More
Antiplatelet

ESC 2019 | THEMIS-PCI: Unlike in the Main Study, Here Ticagrelor Is Indeed Effective

This is a sub-study of the THEMIS presented during the ESC 2019 scientific sessions in Paris, and...
solaci -
Learn More
Antiplatelet

ESC 2019 | THEMIS: Ticagrelor in Diabetics with Stable Coronary Artery Disease

The use of ticagrelor in patients with stable coronary artery disease significantly reduces the rate of major...
solaci -
Learn More
Antiplatelet

ESC 2019 | POPULAR AGE: Good Old Clopidogrel Still Valid

According to this study, presented during the ESC 2019 scientific sessions, non-ST acute coronary syndrome (NSTE-ACS) patients...
solaci -
Learn More
Fellowship

See the Presentations of the 10° ProEducar Fellow Course

Learn about the presentations exhibited during the 10th ProEducar Fellows Course, held in 2019 in the city...
solaci -
Learn More
Institutional News

Download your SOLACI-SBHCI 2019 Congress Certificate

If you took part in the SOLACI-SBHCI 2019 Congress you can get your certificate by sending an...
solaci -
Learn More